Meet Our Team

Meet Our Team




Olivia is an entrepreneur and cannabis & psychedelics business pioneer. She founded one of the first ancillary cannabis companies, Cannabrand in 2013. She also founded several other companies including a tech SaS platform and sales application. Olivia has dedicated her life to destigmatize cannabis and psychedelics, and empowering women. Olivia has been recognized by Forbes, PRWeek’s Top 50 Innovators, Adweek Young Influentials and is a contributor to Adweek and Rolling Stone.

gigi kuo,md



Geraldine (Gigi), MD, conducted her residency at Mount Sinai, in NYC and specializes in pain management and traumatic brain injury (for over 25 years), and has consulted in psychedelic pharma and initial patent filing. Previously, she co-founded Monarch Labs, which has an FDA approved product for chronic wounds, and was a managing director at Athena BioVentures. She has received the Sidney and Elizabeth Licht award for excellence in her writing. Gigi is leading the molecule vision for Felicity Pharma and is confident in tranformorming modern medicine.

Tom Dorozios

Thomas D'Orazio

Chief Operating Officer

Tom started his life science career at Immunex before taking on additional product management responsibilities at Pharmacia and QLT. Tom was Co-founder and CEO of Superna Life Sciences, a specialty pharmaceutical company, and served as CEO of ImmunoPrecise Antibodies where he led the company through its transition to becoming publicly traded. Tom was also most recently the COO of TRYP Therapeutics.

Tom earned a BSc in chemistry from Loyola University Chicago and an MBA from Vanderbilt University.

Dr. Andrew Saich

Dr. Andrew Saich, MD

Chief Medical Officer

Dr. Andrew Saich, MD, has over 20 years experience in pharmaceutical medicine. He recently set up and led the International medical organization at GW Pharmaceuticals and later became Chief Medical Officer at Senzer Pharmaceuticals (inhaled cannabinoids).

Dr Jim Kuo, MD

Dr Jim Kuo, MD

Scientific & Business Advisor

Dr Kuo has extensive expertise across biotech, medical devices, venture capital, pharmaceuticals, psychedelic medicine, capital markets, IPO’s and RTO’s. He has been CEO, Chairman, Co-Founder and he has strong experience in clinical development, particularly across CNS and Neurology.
Josh Woolley

Dr. Josh Woolley

Scientific Advisor

Dr. Josh Woolley is an Associate Professor in Residence in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco (UCSF) as well as a staff psychiatrist in Mental Health at the San Francisco Veterans Affairs Medical Center (SFVAMC). He is Board Certified in Psychiatry by the American Board of Psychiatry and Neurology. He is the Director of the Bonding and Attunement in Neuropsychiatric Disorders (BAND) lab at UCSF that focuses on understanding and treating social deficits in neuropsychiatric disorders including schizophrenia, substance use disorders, and mood disorders. He is also the Director of the Translational Psychedelic Research (TrPR) Program at UCSF, which brings together scientists and care providers across disciplines to understand how psilocybin, LSD, ketamine, MDMA, and related compounds impact the brain and other organ systems.

Dr. David Rubinow

Dr. David Rubinow

Scientific Advisor

Dr. David Rubinow is a Distinguished Professor of Psychiatry and Chair Emeritus at the University of North Carolina-Chapel Hill School of Medicine. Renowned Key Opinion Leader in Women’s Hormonal Mood Disorders in North America. Founded, UNC Chapel Hill, Mood Disorder Program. played a pivotal role in the development of Zulresso, the first FDA and only FDA approved medication for postpartum depression.